CN109438449B - 一种含六氢哒嗪酸结构的西拉普利的合成方法 - Google Patents
一种含六氢哒嗪酸结构的西拉普利的合成方法 Download PDFInfo
- Publication number
- CN109438449B CN109438449B CN201811366308.2A CN201811366308A CN109438449B CN 109438449 B CN109438449 B CN 109438449B CN 201811366308 A CN201811366308 A CN 201811366308A CN 109438449 B CN109438449 B CN 109438449B
- Authority
- CN
- China
- Prior art keywords
- compound
- cilazapril
- mixture
- hexahydropyridazine
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 title claims abstract description 38
- 229960005025 cilazapril Drugs 0.000 title claims abstract description 37
- 239000002253 acid Substances 0.000 title claims description 14
- HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 title claims description 12
- 238000001308 synthesis method Methods 0.000 title abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 23
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims abstract description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 14
- -1 (R) -2-hydroxyphenyl butyric acid ethyl ester Chemical compound 0.000 claims abstract description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract description 9
- 238000010189 synthetic method Methods 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 84
- 238000006243 chemical reaction Methods 0.000 claims description 38
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims description 4
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 claims description 3
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 claims description 3
- HGHOYIFINVBZKO-UHFFFAOYSA-N 2-diphenylphosphanylphenol Chemical compound OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 HGHOYIFINVBZKO-UHFFFAOYSA-N 0.000 claims description 2
- 125000005604 azodicarboxylate group Chemical group 0.000 claims description 2
- IRJKSAIGIYODAN-ISLYRVAYSA-N benzyl (ne)-n-phenylmethoxycarbonyliminocarbamate Chemical compound C=1C=CC=CC=1COC(=O)/N=N/C(=O)OCC1=CC=CC=C1 IRJKSAIGIYODAN-ISLYRVAYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- NCBFTYFOPLPRBX-UHFFFAOYSA-N dimethyl azodicarboxylate Substances COC(=O)N=NC(=O)OC NCBFTYFOPLPRBX-UHFFFAOYSA-N 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- NCBFTYFOPLPRBX-AATRIKPKSA-N methyl (ne)-n-methoxycarbonyliminocarbamate Chemical compound COC(=O)\N=N\C(=O)OC NCBFTYFOPLPRBX-AATRIKPKSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims 7
- 230000035484 reaction time Effects 0.000 claims 2
- USVVENVKYJZFMW-ONEGZZNKSA-N (e)-carboxyiminocarbamic acid Chemical compound OC(=O)\N=N\C(O)=O USVVENVKYJZFMW-ONEGZZNKSA-N 0.000 claims 1
- 239000007810 chemical reaction solvent Substances 0.000 claims 1
- 150000005690 diesters Chemical class 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract description 10
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 abstract description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract description 5
- 238000006482 condensation reaction Methods 0.000 abstract description 2
- 238000011403 purification operation Methods 0.000 abstract description 2
- BZIBRGSBQKLEDC-UHFFFAOYSA-N diazinane-3-carboxylic acid Chemical group OC(=O)C1CCCNN1 BZIBRGSBQKLEDC-UHFFFAOYSA-N 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- HVLLSGMXQDNUAL-UHFFFAOYSA-N triphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- QRKPPWPLSQRGSU-UHFFFAOYSA-N diazepine-1-carboxylic acid Chemical compound OC(=O)N1C=CC=CC=N1 QRKPPWPLSQRGSU-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- UDJNHUAEPSYCRU-LLVKDONJSA-N ethyl (2r)-4-phenyl-2-(trifluoromethylsulfonyloxy)butanoate Chemical compound CCOC(=O)[C@H](OS(=O)(=O)C(F)(F)F)CCC1=CC=CC=C1 UDJNHUAEPSYCRU-LLVKDONJSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种含六氢哒嗪酸结构的西拉普利的简便合成方法,(1S,9S)‑9‑氨基‑10‑氧代‑6H‑哒嗪并[1,2‑a][1,2]二氮杂‑1‑羧酸叔丁酯(Ⅱ)与(R)‑2‑羟基苯丁酸乙酯(Ⅲ)在0~60℃、三苯基膦、偶氮二羧酸二酯的作用下发生Mitsunobu缩合反应,生成(1S,9S)‑9‑[(1S)‑乙氧羰基‑3‑苯丙氨基]八氢‑10‑氧代‑6H‑哒嗪并[1,2‑a][1,2]二氮杂‑1‑羧酸叔丁酯(Ⅳ)和(1S,9S)‑9‑[[(1S)‑乙氧羰基‑3‑苯丙基]氨基]八氢‑10‑氧代‑6H‑哒嗪并[1,2‑a][1,2]二氮杂‑1‑羧酸叔丁酯三苯基磷盐(Ⅴ)的混合物,该混合物在盐酸水溶液作用下,得到西拉普利粗品,随后经重结晶后得到西拉普利(Ⅰ)。本发明的合成方法减少了提纯操作步骤、操作简单,避免了昂贵的三氟甲磺酸酐、以及具有难闻气味的吡啶的使用,适合工业化生产。
Description
技术领域
本发明涉及一种抗高血压药物西拉普利的合成,具体涉及一种含六氢哒嗪酸结构的西拉普利的合成方法。
背景技术
西拉普利(Cilazpril,Ⅰ),化学名为(1S,9S)-9-[[(1S)-1-(乙氧羰基)-3-苯基丙基]氨基]八氢-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸,由瑞士Roche公司研发,1990年首先在英国上市。它是一种非巯基血管紧张素转化酶(ACE)抑制剂,可以抑制血浆中ACE活性和血管紧张素Ⅰ引起的血压升高,增强缓激肽的降压作用,抑制血管壁去甲肾上腺素引起的血管紧张素Ⅱ的释放。西拉普利降压、抑制ACE、拮抗血管紧张素Ⅰ的加压反应和作用时间比卡托普利和依那普利优越,本品临床用于轻度和中度原发性、顽固性高血压的治疗。
文献报道的西拉普利合成方法都是以(1S,9S)-9-氨基-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸酯为关键前体。例如,专利US4512924描述了由(1S,9S)-9-氨基-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸叔丁酯(Ⅱ)与(R)-1-(乙氧羰基)-3-苯基丙基三氟甲磺酸酯(Ⅵ)在碱的作用下缩合,得到化合物(Ⅳ),随后经过脱叔丁基和重结晶得到西拉普利(Ⅰ);又如,专利CA2500558和WO2001083458描述了(1S,9S)-9-氨基-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸苄酯(Ⅶ)与化合物(Ⅵ)在碱作用下缩合生成化合物(Ⅷ),随后经氢化和重结晶得到西拉普利(Ⅰ)。这两种方法都需要用到化合物(Ⅵ)。化合物(Ⅵ)的合成要用到价格昂贵的三氟甲磺酸酐,导致成本上升;还需要用难闻的吡啶,且吡啶在后处理中很难清除干净。化合物(Ⅵ)不稳定,需要现做现用,给生产带来了不便,而在缩合条件下,化合物(Ⅵ)也易发生分子内的消除,导致化合物(Ⅵ)用量较大、反应收率低。
发明内容
本发明的目的在于克服现有技术的不足之处,提供了一种含六氢哒嗪酸结构的西拉普利的合成方法,原料易得、操作简单、反应条件温和,可以高收率、高纯度地得到目标化合物,避免了使用昂贵的三氟甲磺酸酐,同时也避免了使用具有难闻气味的吡啶。
具体而言,本发明包含以下几个步骤:
(a)在三苯基膦和偶氮二羧酸二酯作用下,(1S,9S)-9-氨基-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸叔丁酯(Ⅱ)与(R)-2-羟基苯丁酸乙酯(Ⅲ)发生Mitsunobu缩合反应,生成(1S,9S)-9-[(1S)-乙氧羰基-3-苯丙氨基]八氢-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸叔丁酯(Ⅳ)和(1S,9S)-9-[[(1S)-乙氧羰基-3-苯丙基]氨基]八氢-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸叔丁酯三苯基磷盐(Ⅴ)的混合物;
(b)化合物(Ⅳ)和化合物(Ⅴ)的混合物在盐酸水溶液作用下,得到西拉普利粗品,随后经重结晶得到西拉普利(Ⅰ)。
本发明涉及到的反应可以用如下的反应式来表示:
本发明所述从化合物(Ⅱ)和化合物(Ⅲ)制备化合物(Ⅳ)和化合物(Ⅴ)混合物的反应是在三苯基膦作用下进行的,所用的三苯基膦的用量优选为化合物(Ⅱ)的1.0~5.0当量。
本发明所述从化合物(Ⅱ)和化合物(Ⅲ)制备化合物(Ⅳ)和化合物(Ⅴ)混合物的反应是在偶氮二羧酸二酯作用下进行的,所述的偶氮二羧酸二酯为偶氮二甲酸二甲酯、偶氮二甲酸二乙酯、偶氮二甲酸二异丙酯、偶氮二甲酸二叔丁酯、偶氮二甲酸二苄酯、偶氮二甲酸二(对氯苄基)酯中至少一种;R基选自甲基、乙基、异丙基、叔丁基、苄基、对氯苄基。所用的偶氮二羧酸二酯的用量优选为化合物(Ⅱ)的1.0~5.0当量。
本发明所述从化合物(Ⅱ)和化合物(Ⅲ)制备化合物(Ⅳ)和化合物(Ⅴ)混合物的反应中,反应温度为0~60℃。
本发明所述从化合物(Ⅱ)和化合物(Ⅲ)制备化合物(Ⅳ)和化合物(Ⅴ)混合物的反应完成后无需提纯处理,直接进行下一步反应。
本发明所述从化合物(Ⅱ)和化合物(Ⅲ)制备化合物(Ⅳ)和化合物(Ⅴ)混合物的反应的操作过程大致如下:
在反应瓶中加入化合物(Ⅱ)、化合物(Ⅲ)、三苯基膦、四氢呋喃,滴加偶氮二羧酸二酯,在0~60℃下反应1~24小时。反应完后,直接用作下一步反应。
本发明所述从化合物(Ⅳ)和化合物(Ⅴ)混合物制备西拉普利(Ⅰ)的反应中,反应温度为10~65℃。
本发明所述从化合物(Ⅳ)和化合物(Ⅴ)混合物制备西拉普利(Ⅰ)的反应的操作过程大致如下:
往上一步的反应液中加入盐酸水溶液,在10~65℃下反应1~24小时。反应完成后,减压除去四氢呋喃。加入乙酸乙酯萃取,分出水层。水层用碱中和至pH为5~6,析出固体,抽滤,经重结晶后得到西拉普利(Ⅰ)。
本技术方案与背景技术相比,本发明的优点在于:1.采用(R)-2-羟基苯丁酸乙酯(Ⅲ)与化合物(Ⅱ)缩合,避免了昂贵的三氟甲磺酸酐和难闻的吡啶的使用;2.(R)-2-羟基苯丁酸乙酯(Ⅲ)与化合物(Ⅱ)缩合得到化合物(Ⅳ)和化合物(Ⅴ)混合物。化合物(Ⅴ)遇到水会转化成(1S,9S)-9-[[(1S)-乙氧羰基-3-苯丙基](羟基三苯基膦)氨基]八氢-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸叔丁酯(Ⅸ)。化合物(Ⅳ)和化合物(Ⅴ)在酸的作用下会同时发生脱叔丁基反应以及氮磷键的水解反应,转化为西拉普利(Ⅰ)。从化合物(Ⅴ)水解而来的化合物(Ⅸ)在酸的作用下,也能同时发生脱叔丁基反应以及氮磷键的水解反应,转化为西拉普利(Ⅰ)。因此,该路线第一步反应无需进行任何后处理,直接用于下一步反应,简化了操作,提高了收率,降低了成本。
具体实施方式
下面通过实施例具体说明本发明的内容:
实施例1:(1S,9S)-9-[(1S)-乙氧羰基-3-苯丙氨基]八氢-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸叔丁酯(Ⅳ)和(1S,9S)-9-[[(1S)-乙氧羰基-3-苯丙基]氨基]八氢-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸叔丁酯三苯基磷盐(Ⅴ)混合物的合成
在反应瓶中加入化合物Ⅱ(56.7g,0.2mol)、化合物Ⅲ(62.5g,0.3mol)、三苯基磷(209.8g,0.8mol)和四氢呋喃(1L)。0℃下,滴加偶氮二甲酸二异丙酯(161.7g,0.8mol),滴完后室温反应10h。反应完成后,无需提纯,直接投入下一步反应。
取出少量反应液旋干,得到油状物。将油状物进行柱层析分离(二氯甲烷:甲醇=5:1),得到0.84g化合物(Ⅳ)和1.1g化合物(Ⅸ)(由化合物Ⅴ转化而来)。化合物(Ⅳ):1H-NMR(400MHz,CDCl3)δ:1.25-1.40(m,4H),1.46(s,9H),1.45-1.50(m,1H),1.65-1.80(m,3H),1.95-2.09(m,3H),2.28-2.31(d,J=11.2Hz,1H),2.49-2.53(m,1H),2.72-2.78(m,2H),2.93-2.96(d,J=13.6Hz,1H),3.05-3.11(t,J=12.2Hz,1H),3.35-3.44(m,2H),4.10-4.25(m,4H),4.95-4.96(d,J=5.2Hz,1H),7.15-7.30(m,5H).化合物(Ⅸ)(由化合物Ⅴ转化而来):1H-NMR(400MHz,CDCl3)δ:1.28-1.38(m,4H),1.46(s,9H),1.48-1.51(m,1H),1.65-1.78(m,3H),1.93-2.09(m,4H),2.28-2.34(d,J=12.0Hz,1H),2.49-2.55(m,1H),2.72-2.77(m,2H),2.94-2.97(d,J=13.2Hz,1H),3.05-3.11(m,1H),3.38-3.45(m,2H),4.10-4.28(m,4H),4.94-4.96(d,J=5.0Hz,1H),7.17-7.31(m,11H),7.55-7.63(m,10H).
实施例2:(1S,9S)-9-[[(1S)-1-(乙氧羰基)-3-苯基丙基]氨基]八氢-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸(Cilazapril)(Ⅰ)的合成
往实施例1中得到的反应液中加入2mol/L盐酸水溶液(1L),室温反应16h。待反应完全后,减压蒸除四氢呋喃,向残留物中加入乙酸乙酯(1L),萃取,分出水层。水层再用乙酸乙酯(1L)萃取一次,HPLC显示水相中无残留的三苯基氧膦。水层用饱和氢氧化钠水溶液调pH至5~6,有大量固体析出,过滤,95%乙醇重结晶得白色固体64.4g,两步收率74%,HPLC纯度99.92%,mp 97~99℃,[α]D 20=-60.5°(C=1,ethanol);ESI-MS m/z:418.5[M+H]+;1H-NMR(400MHz,DMSO-d6)δ:1.25(t,J=4.8Hz,3H),1.30-1.40(m,1H),1.58-1.80(m,4H),1.98-2.23(m,4H),2.58-2.69(m,2H),2.96-2.98(d,J=6.0Hz,2H),3.22-3.30(m,3H),3.75-3.79(m,1H),4.17-4.19(m,2H),4.55-4.80(m,2H),7.16-7.30(m,5H),9.42(s,1H)。
实施例3:(1S,9S)-9-[(1S)-乙氧羰基-3-苯丙氨基]八氢-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸叔丁酯(Ⅳ)和(1S,9S)-9-[[(1S)-乙氧羰基-3-苯丙基]氨基]八氢-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸叔丁酯三苯基磷盐(Ⅴ)混合物的合成
在反应瓶中加入化合物Ⅱ(56.7g,0.2mol)、化合物Ⅲ(50.0g,0.24mol)、三苯基磷(157.3g,0.6mol)和四氢呋喃(1.2L)。50℃下,滴加偶氮二甲酸二乙酯(104.4g,0.6mol),时间约1h,滴完后即反应完全,无需进行提纯操作,直接投入下一步。
实施例4:(1S,9S)-9-[[(1S)-1-(乙氧羰基)-3-苯基丙基]氨基]八氢-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸(Cilazapril)(Ⅰ)的合成
往实施例3中得到的反应液中加入2mol/L盐酸水溶液(1.2L),室温反应16h。待反应完全后,减压蒸除四氢呋喃,向残留物中加入乙酸乙酯(1.2L),萃取,分出水层。水层再用乙酸乙酯(1.2L)萃取一次,HPLC显示水相中无残留的三苯基氧膦。水层用饱和氢氧化钠水溶液调pH至5~6,有大量固体析出,过滤,95%乙醇重结晶得白色固体59.2g,两步收率68%,HPLC纯度99.65%。
实施例5:化合物(Ⅸ)转化为西拉普利(Cilazapril)(Ⅰ)
在反应瓶中加入实施例1中柱层析得到的化合物(Ⅸ)1.0g、四氢呋喃10mL、2mol/L盐酸水溶液(10mL),室温反应16h。待反应完全后,减压蒸除四氢呋喃,向残留物中加入乙酸乙酯(10mL),萃取,分出水层。水层用饱和氢氧化钠水溶液调pH至5~6,有固体析出,过滤,得白色固体0.52g,收率89%。
以上所述,仅为本发明较佳实施例而已,故不能依此限定本发明实施的范围,即依本发明专利范围及说明书内容所作的等效变化与修饰,皆应仍属本发明涵盖的范围内。
Claims (9)
1.一种含六氢哒嗪酸结构的西拉普利的合成方法,包含如下步骤:
(a)、(1S,9S)-9-氨基-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸叔丁酯(Ⅱ)与(R)-2-羟基苯丁酸乙酯(Ⅲ)在三苯基膦、偶氮二羧酸二酯的作用下生成(1S,9S)-9-[(1S)-乙氧羰基-3-苯丙氨基]八氢-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸叔丁酯(Ⅳ)和(1S,9S)-9-[[(1S)-乙氧羰基-3-苯丙基]氨基]八氢-10-氧代-6H-哒嗪并[1,2-a][1,2]二氮杂-1-羧酸叔丁酯三苯基磷盐(Ⅴ)的混合物;
所述的偶氮二羧酸二酯为偶氮二甲酸二甲酯、偶氮二甲酸二乙酯、偶氮二甲酸二异丙酯、偶氮二甲酸二叔丁酯、偶氮二甲酸二苄酯、偶氮二甲酸二(对氯苄基)酯中至少一种;所述R基选自甲基、乙基、异丙基、叔丁基、苄基、对氯苄基;
(b)、化合物(Ⅳ)和化合物(Ⅴ)的混合物在盐酸水溶液的作用下,生成西拉普利粗品,随后经重结晶得到西拉普利(Ⅰ);
2.根据权利要求1所述的含六氢哒嗪酸结构的西拉普利的合成方法,其特征在于:从化合物(Ⅱ)和化合物(Ⅲ)制备化合物(Ⅳ)和化合物(Ⅴ)的混合物的反应是在三苯基膦作用下进行的,三苯基膦的用量为化合物(Ⅱ)的1.0~5.0当量。
3.根据权利要求1所述的含六氢哒嗪酸结构的西拉普利的合成方法,其特征在于:从化合物(Ⅱ)和化合物(Ⅲ)制备化合物(Ⅳ)和化合物(Ⅴ)的混合物的反应是在偶氮二羧酸二酯的作用下进行的,所用的偶氮二羧酸二酯的用量为化合物(Ⅱ)的1.0~5.0当量。
4.根据权利要求1所述的含六氢哒嗪酸结构的西拉普利的合成方法,其特征在于:从化合物(Ⅱ)和化合物(Ⅲ)制备化合物(Ⅳ)和化合物(Ⅴ)的混合物的反应温度为0~60℃。
5.根据权利要求1所述的含六氢哒嗪酸结构的西拉普利的合成方法,其特征在于:从化合物(Ⅱ)和化合物(Ⅲ)制备化合物(Ⅳ)和化合物(Ⅴ)的混合物的反应时间为1~24小时。
6.根据权利要求1所述的含六氢哒嗪酸结构的西拉普利的合成方法,其特征在于:从化合物(Ⅱ)和化合物(Ⅲ)制备化合物(Ⅳ)和化合物(Ⅴ)的混合物的反应溶剂为四氢呋喃。
7.根据权利要求1所述的含六氢哒嗪酸结构的西拉普利的合成方法,其特征在于:从化合物(Ⅳ)和化合物(Ⅴ)的混合物制备西拉普利(Ⅰ)的反应温度为10~65℃。
8.根据权利要求1所述的含六氢哒嗪酸结构的西拉普利的合成方法,其特征在于:从化合物(Ⅳ)和化合物(Ⅴ)的混合物制备西拉普利(Ⅰ)的反应时间为1~24小时。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811366308.2A CN109438449B (zh) | 2018-11-16 | 2018-11-16 | 一种含六氢哒嗪酸结构的西拉普利的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811366308.2A CN109438449B (zh) | 2018-11-16 | 2018-11-16 | 一种含六氢哒嗪酸结构的西拉普利的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109438449A CN109438449A (zh) | 2019-03-08 |
CN109438449B true CN109438449B (zh) | 2020-08-11 |
Family
ID=65554474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811366308.2A Active CN109438449B (zh) | 2018-11-16 | 2018-11-16 | 一种含六氢哒嗪酸结构的西拉普利的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109438449B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005003134A1 (en) * | 2003-07-07 | 2005-01-13 | Hetero Drugs Limited | A novel process for the preparation of cilazapril |
JP2005281246A (ja) * | 2004-03-30 | 2005-10-13 | Konica Minolta Chemical Co Ltd | シラザプリルの製造方法。 |
CN101560204A (zh) * | 2009-05-15 | 2009-10-21 | 浙江华海药业股份有限公司 | 一种制备抗高血压药物西拉普利中间体及制备方法 |
WO2012049646A1 (en) * | 2010-10-12 | 2012-04-19 | Ranbaxy Laboratories Limited | Process for the preparation of an intermediate of cilazapril |
CN106349230A (zh) * | 2016-08-09 | 2017-01-25 | 浙江医药高等专科学校 | 一种含硝基噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途 |
-
2018
- 2018-11-16 CN CN201811366308.2A patent/CN109438449B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005003134A1 (en) * | 2003-07-07 | 2005-01-13 | Hetero Drugs Limited | A novel process for the preparation of cilazapril |
JP2005281246A (ja) * | 2004-03-30 | 2005-10-13 | Konica Minolta Chemical Co Ltd | シラザプリルの製造方法。 |
CN101560204A (zh) * | 2009-05-15 | 2009-10-21 | 浙江华海药业股份有限公司 | 一种制备抗高血压药物西拉普利中间体及制备方法 |
WO2012049646A1 (en) * | 2010-10-12 | 2012-04-19 | Ranbaxy Laboratories Limited | Process for the preparation of an intermediate of cilazapril |
CN106349230A (zh) * | 2016-08-09 | 2017-01-25 | 浙江医药高等专科学校 | 一种含硝基噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途 |
Also Published As
Publication number | Publication date |
---|---|
CN109438449A (zh) | 2019-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1329445C (en) | Process for preparing n-[1(s)-ethoxycarbonyl-3- phenylpropyl]-l-alanyl-l-proline | |
CZ384697A3 (cs) | Způsob přípravy kyseliny (S)-3-(aminomethyl)-5-methylhexanové | |
JPH06199807A (ja) | イミダゾール誘導体類の合成中間体 | |
EP2046728A1 (en) | Process for preparing pregabalin and its opposite enantiomer | |
CA2608388A1 (en) | A process for the dynamic resolution of (substituted) (r) - or (s) -mandelic acid | |
US20170113988A1 (en) | Terpene-derived compounds and methods for preparing and using same | |
KR100712003B1 (ko) | 펜세린 및 그 유사체의 제조방법 | |
CA2699580C (en) | Process from shikimic acid to oseltamivir phosphate | |
CN109438449B (zh) | 一种含六氢哒嗪酸结构的西拉普利的合成方法 | |
IE58243B1 (en) | A process for the preparation of optically-active 3-amino carboxylic acids | |
JPH03236359A (ja) | 環状アミノ酸抗けいれん性化合物の改良製法 | |
EP0381959B1 (en) | Cyclohexaneacetamide derivatives | |
Yamada et al. | Optically active cyclohexene derivative as a new antisepsis agent: an efficient synthesis of ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl) sulfamoyl] cyclohex-1-ene-1-carboxylate (TAK-242) | |
WO1990003386A1 (de) | Verfahren zur herstellung von dipeptiden mit c-terminalen nicht-proteinogenen aminosäuren | |
JP2020070296A (ja) | リナグリプチンの製造法 | |
JP4199318B2 (ja) | キラルで、非ラセミの(4−アリール−2,5−ジオキソイミダゾリジン−1−イル)酢酸の製造方法 | |
JP3699769B2 (ja) | ペプチド型化合物 | |
CN114989045B (zh) | 合成奈玛特韦的中间体及其制法以及合成奈玛特韦的方法 | |
EP0432898B1 (en) | Glutaric acid derivatives and preparation thereof | |
EP2448916B1 (en) | Production of trans-4-aminocyclopent-2-ene-1-carboxylic acid derivatives | |
EP1185498A2 (en) | Synthesis of optically active cyclohexylphenylglycolic acid and its esters | |
KR100465142B1 (ko) | 정제알킬알킬아세토아세테이트의제조방법 | |
Tseng et al. | Enantioselective Synthesis of N‐[(S)‐Ethoxycarbonyl‐3‐phenylpropyl]‐L‐alanyl‐L‐proline from Chiral Synthon Prepared Enzymatically; A Practical Method for Large‐Scale Synthesis | |
KR100199042B1 (ko) | 2-아미노티아졸카르복시산 유도체의 제조방법 | |
WO2012049646A1 (en) | Process for the preparation of an intermediate of cilazapril |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |